Back
Top 28%
22.9%
Top 35%
6.6%
Top 0.8%
6.6%
Top 4%
5.7%
Top 2%
5.2%
Top 0.9%
4.3%
Top 3%
4.0%
Top 0.3%
3.3%
Top 6%
2.9%
Top 1%
2.0%
Top 1%
2.0%
Top 53%
1.6%
Top 9%
1.6%
Top 5%
1.6%
Top 3%
1.6%
Top 28%
1.6%
Top 4%
1.4%
Top 0.9%
1.4%
Top 13%
1.2%
Top 2%
1.2%
Top 23%
1.2%
Top 13%
0.7%
Top 5%
0.7%
Top 6%
0.7%
Comparison of outcomes of second-line durvalumab plus tremelimumab and lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
2026-01-11
gastroenterology
Title + abstract only
View on medRxiv
Show abstract
Background and AimThe optimal second-line therapy following first-line atezolizumab plus bevacizumab (Atezo/Beva) remains unascertained. This study compared second-line durvalumab plus tremelimumab (Dur/Tre) with lenvatinib (Len) after first-line Atezo/Beva in unresectable hepatocellular carcinoma (uHCC). MethodsThis prospectively registered cohort study analyzed patients with uHCC who received Dur/Tre (n = 14) or Len (n = 67) as second-line therapy after first-line Atezo/Beva. Tumor response w...
Predicted journal destinations
1
PLOS ONE
1737 training papers
2
Scientific Reports
701 training papers
3
American Journal of Gastroenterology
15 training papers
4
Cancers
57 training papers
5
Frontiers in Medicine
99 training papers
6
Gut
17 training papers
7
Vaccines
131 training papers
8
Heliyon
57 training papers
9
Journal of Clinical Medicine
77 training papers
10
Medicine
29 training papers
11
Gut Microbes
15 training papers
12
BMJ Open
553 training papers
13
Cureus
64 training papers
14
Frontiers in Oncology
34 training papers
15
BMC Cancer
21 training papers
16
eLife
262 training papers
17
Cancer Medicine
17 training papers
18
Biomedicines
21 training papers
19
Journal of Medical Internet Research
81 training papers
20
Frontiers in Pharmacology
27 training papers
21
BMC Medicine
155 training papers
22
Frontiers in Immunology
140 training papers
23
British Journal of Cancer
22 training papers
24
Diagnostics
36 training papers